Ma'en Obeidat,Ke Hao,Yohan Bossé,David C Nickle,Yunlong Nie,Dirkje S Postma,Michel Laviolette,Andrew J Sandford,Denise D Daley,James C Hogg,W Mark Elliott,Nick Fishbane,Wim Timens,Pirro G Hysi,Jaakko Kaprio,James F Wilson,Jennie Hui,Rajesh Rawal,Holger Schulz,Beate Stubbe,Caroline Hayward,Ozren Polasek,Marjo-Riitta Järvelin,Jing Hua Zhao,Deborah Jarvis,Mika Kähönen,Nora Franceschini,Kari E North,Daan W Loth,Guy G Brusselle,Albert Vernon Smith,Vilmundur Gudnason,Traci M Bartz,Jemma B Wilk,George T O'Connor,Patricia A Cassano,Wenbo Tang,Louise V Wain,María Soler Artigas,Sina A Gharib,David P Strachan,Don D Sin,Martin D Tobin,Stephanie J London,Ian P Hall,Peter D Paré

Abstract:Lung function measures reflect the physiological state of the lung, and are essential to the diagnosis of chronic obstructive pulmonary disease (COPD). The SpiroMeta-CHARGE consortium undertook the largest genome-wide association study (GWAS) so far (n=48,201) for forced expiratory volume in 1 s (FEV1) and the ratio of FEV1 to forced vital capacity (FEV1/FVC) in the general population. The lung expression quantitative trait loci (eQTLs) study mapped the genetic architecture of gene expression in lung tissue from 1111 individuals. We used a systems genetics approach to identify single nucleotide polymorphisms (SNPs) associated with lung function that act as eQTLs and change the level of expression of their target genes in lung tissue; termed eSNPs.The SpiroMeta-CHARGE GWAS results were integrated with lung eQTLs to map eSNPs and the genes and pathways underlying the associations in lung tissue. For comparison, a similar analysis was done in peripheral blood. The lung mRNA expression levels of the eSNP-regulated genes were tested for associations with lung function measures in 727 individuals. Additional analyses identified the pleiotropic effects of eSNPs from the published GWAS catalogue, and mapped enrichment in regulatory regions from the ENCODE project. Finally, the Connectivity Map database was used to identify potential therapeutics in silico that could reverse the COPD lung tissue gene signature.SNPs associated with lung function measures were more likely to be eQTLs and vice versa. The integration mapped the specific genes underlying the GWAS signals in lung tissue. The eSNP-regulated genes were enriched for developmental and inflammatory pathways; by comparison, SNPs associated with lung function that were eQTLs in blood, but not in lung, were only involved in inflammatory pathways. Lung function eSNPs were enriched for regulatory elements and were over-represented among genes showing differential expression during fetal lung development. An mRNA gene expression signature for COPD was identified in lung tissue and compared with the Connectivity Map. This in-silico drug repurposing approach suggested several compounds that reverse the COPD gene expression signature, including a nicotine receptor antagonist. These findings represent novel therapeutic pathways for COPD.The system genetics approach identified lung tissue genes driving the variation in lung function and susceptibility to COPD. The identification of these genes and the pathways in which they are enriched is essential to understand the pathophysiology of airway obstruction and to identify novel therapeutic targets and biomarkers for COPD, including drugs that reverse the COPD gene signature in silico.The research reported in this article was not specifically funded by any agency. See Acknowledgments for a full list of funders of the lung eQTL study and the Spiro-Meta CHARGE GWAS.

Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function

Meta-analysis of Exome Array Data Identifies Six Novel Genetic Loci for Lung Function

Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets

Multiethnic meta-analysis identifies ancestry-specific and cross-ancestry loci for pulmonary function

Multi-ancestry Genome-Wide Association Analyses Improve Resolution of Genes and Pathways Influencing Lung Function and Chronic Obstructive Pulmonary Disease Risk

Multi-ancestry genome-wide association study reveals novel genetic signals for lung function decline

Molecular Mechanisms Underlying Variations in Lung Function: a Systems Genetics Analysis

Assessing the contribution of rare genetic variants to phenotypes of chronic obstructive pulmonary disease using whole-genome sequence data

A large-scale genome-wide association analysis of lung function in the Chinese population identifies novel loci and highlights shared genetic aetiology with obesity

Rare and low-frequency exonic variants and gene-by-smoking interactions in pulmonary function

Gene Network Analysis in a Pediatric Cohort Identifies Novel Lung Function Genes.

Omega-3 Fatty Acids and Genome-Wide Interaction Analyses Reveal DPP10–Pulmonary Function Association

Breathing new life into the study of COPD with genes identified from genome-wide association studies

A Genome-Wide Association Study in Chronic Obstructive Pulmonary Disease (COPD): Identification of Two Major Susceptibility Loci

Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer

Genetic correlation and causal relationships between cardio-metabolic traits and lung function impairment

Leveraging lung tissue transcriptome to uncover candidate causal genes in COPD genetic associations

Common Genes Underlying Asthma and COPD? Genome-wide Analysis on the Dutch Hypothesis

Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis

Informed genome-wide association analysis with family history as a secondary phenotype identifies novel loci of lung cancer.